Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIPC GLP-1
NCT02746757Completed
- Sponsor
- Karolinska Institutet
- Start
- May 2015
- Primary completion
- Dec 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of exendin 9-39 in ischemia-reperfusion injury (IRI) (3 arms), sponsored by Karolinska Institutet. Primary endpoint: Change in endothelium dependent vasodilatation. Started May 2015; status: completed.
02
Drugs
exendin 9-39
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT02746757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02746757.